Market access advancements and challenges in “drug-companion diagnostic test” co-development in Europe

Journal of Personalized Medicine

Volumn 5, Issue 2, 2015, Pages 213-228

  Akhmetov, Ildar ^a   Ramaswamy, Rakshambikai ^a   Akhmetov, Illias ^b   Thimmaraju, Phani Kishore ^a  

^a Phamax Analytic Resources Pvt Ltd   (India)

^b Unicorn   (Ukraine)

Author keywords

Companion diagnostics; Cost effectiveness; Market access; Stratified medicine; Value addition

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; CRIZOTINIB; TRASTUZUMAB; VEMURAFENIB;

CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMMERCIAL PHENOMENA; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG COMPANION DIAGNOSTIC TEST; DRUG SURVEILLANCE PROGRAM; EUROPE; HUMAN; NON SMALL CELL LUNG CANCER; OUTCOMES RESEARCH; PROSPECTIVE PRICING; REIMBURSEMENT; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 84977860906     PISSN: None     EISSN: 20754426     Source Type: Journal    
DOI: 10.3390/jpm5020213     Document Type: Review

References (34)

1. Womack, C. The Pathologist in Drug Development. Available online: http://www.pathsoc.org/files/meetings/edinburghprestues/1150%20Tues%20Fintry%20Womack.pdf (accessed on 1 February 2015).
2. Miller, I.; Ashton-Chess, J.; Spolders, H.; Fert, V.; Ferrara, J.; Kroll, W.; Askaa, J.; Larcier, P.; Terry, P.F.; Bruinvels, A., et al. Market access challenges in the EU for high medical value diagnostic tests. Pers. Med. 2011, 8, 137–148.
3. Thompson, D.F.; Sharp, R.P. Identification and reduction of adverse drug reactions. J. Healthc. Leadersh. 2010, 2010, 43–48.
4. EDMA. European IVD Market Statistics. Available online: http://www.edma-ivd.eu/index.php?page=European-IVD-Market-Statistics-Reports (accessed on 1 February 2015).
5. Markus B.; Brüggenjürgen, B.; Stefan, W. Personalised Medicine in Europe—Enhancing Patient Access to Pharmaceutical Drug-Diagnostic Companion Products. Available online: http://www.epemed.org/online/www/content2/104/107/910/pagecontent2/4339/791/ENG/EpemedWhitePaperNOV14.pdf (accessed on 1 February 2015).
6. Trakas, K. Responding to the Challenges of Personalized Medicine: Back to Basics-Again. Available online: http://www.ispor.org/meetings/baltimore0511/presentations/IP4_Kostas-Trakas-Slides.pdf (accessed on 1 February 2015).
7. Falconi, A.; Lopes, G.; Parker, J.L. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer. J. Thorac. Oncol. 2014, 9, 163–169.
8. Blair, E.D.; Stratton, E.K.; Kaufmann, M. Aligning the economic value of companion diagnostics and stratified medicines. J. Pers. Med. 2012, 2, 257–266.
9. Walker, I.; Newell, H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Dis. 2009, 8, 15–16.
10. Plexxikon Announces FDA Approval of Zelboraftm (Vemurafenib) and Companion Diagnostic for the Treatment of Patients with braf Mutation-Positive Metsatatic Melanoma. Available online: http://www.plexxikon.com/view.cfm/95/press-releases (accessed on 1 May 2015).
11. European Commission. Use of “-omics” Technologies in the Development of Personalised Medicine. Available online: http://ec.europa.eu/health/files/latest_news/2013–10_personalised_medicine_en.pdf (accessed on 1 February 2015).
12. Olsen, D.; Jorgensen, J.T. Companion diagnostics for targeted cancer drugs—Clinical and regulatory aspects. Front. Oncol. 2014, 4, doi:10.3389/fonc.2014.00105.
13. EMA. Reflection Paper on Methodological Issues Associated with Pharmacogenomic Biomarkers in Relation to Clinical Development and Patient Selection. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500108672.pdf (accessed on 1 February 2015).
14. FDA. List of Cleared or Approved Companion Diagnostic Devices (in vitro and Imaging Tools). Available online: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm (accessed on 1 February 2015).
15. European Commission. Proposal for a Regulation of the European Parliament and of the Council on in vitro Diagnostic Medical Devices. Available online: http://ec.europa.eu/health/medical-devices/files/revision_docs/proposal_2012_541_en.pdf (accessed on 1 February 2015).
16. EAPM. Innovation and Patient Access to Personalised Medicine—Action Plan. Available online: http://euapm.eu/wp-content/uploads/2012/07/EAPM-REPORT-on-Innovation-and-Patient-Access-to-Personalised-Medicine.pdf (accessed on 1 February 2015).
17. EDMA. Revision of Directive 98/79/ec on in vitro Diagnostic Medical Devices. Available online: http://www.edma-ivd.be/uploads/PositionPapers/EDMA_2014–24–01_IVD_PP_FIN.pdf (accessed on 1 February 2015).
18. OECD. Health Status. Available online: http://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT (accessed on 1 February 2015).
19. Tooke, P.S.J. The Future of Healthcare in Europe. Available online: http://www.ucl.ac.uk/european-institute/analysis-publications/publications/FHE_FINAL_online.pdf (accessed on 1 February 2015).
20. Cohen, J.P.; Felix, A.E. Personalized medicine’s bottleneck: Diagnostic test evidence and reimbursement. J. Pers. Med. 2014, 4, 163–175.
21. Schackman, B.R.; Scott, C.A.; Walensky, R.P.; Losina, E.; Freedberg, K.A.; Sax, P.E. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008, 22, 2025–2033.
22. Mittmann, N.; Au, H.J.; Tu, D.; O’Callaghan, C.J.; Isogai, P.K.; Karapetis, C.S.; Zalcberg, J.R.; Evans, W.K.; Moore, M.J.; Siddiqui, J., et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of national cancer institute of canada clinical trials group CO.17 trial. J. Nat. Cancer Inst. 2009, 101, 1182–1192.
23. Atherly, A.J.; Camidge, D.R. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br. J. Cancer 2012, 106, 1100–1106.
24. Vogenberg, F.R.; Barash, C.I.; Pursel, M. Personalized medicine: Part 2: Ethical, legal, and regulatory issues. Pharm. Ther. 2010, 35, 624–642.
25. Faulkner, E.; Annemans, L.; Garrison, L.; Helfand, M.; Holtorf, A.P.; Hornberger, J.; Hughes, D.; Li, T.; Malone, D.; Payne, K. et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ispor personalized medicine special interest group. Value Health 2012, 15, 1162–1171.
26. Wasted Medicines Waste Money. Available online: http://www.medicinewaste.com/didyouknow (accessed on 1 March 2015).
27. Ewen, M. The Cost of Irrartional Medicinal Use. Available online: http://whocc.goeg.at/Downloads/Conference2011/PraesentationenPPRIKonferenz/Day1_afternoon_Theatersaal_1500_Ewen.pdf (accessed on 1 March 2015).
28. Petty, G.W.; Brown, R.D., Jr.; Whisnant, J.P.; Sicks, J.D.; O’Fallon, W.M.; Wiebers, D.O. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study. Ann. Int. Med. 1999, 130, 14–22.
29. Higashi, M.K.; Veenstra, D.L.; Kondo, L.M.; Wittkowsky, A.K.; Srinouanprachanh, S.L.; Farin, F.M.; Rettie, A.E. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287, 1690–1698.
30. Kievits, T. Personalised medicine in clinical practice. Available online: http://innovationforhealth.nl/Documenten/Diagnosis-Tim-Kievits.pdf (accessed on 1 March 2015).
31. Garfield, S. Advancing Access to Personalized Medicine: A Comparative Assessment of European Reimbursement Systems. Available online: http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/pmc_bridgehead_issue_brief_european_reimbursement.pdf (accessed on 1 March 2015).
32. Kanavos, P.; Ferrario, A. Managed Entry Agreements for Pharmaceuticals: The European Experience. Available online: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/mea_report_en.pdf (accessed on 1 March 2015).
33. Groves, E. From Biomarkers to Diagnostics: The Road to Success. Available online: http://www.quintiles.com/~/media/library/white%20papers/biomarkers-diagnostics.pdf (accessed on 1 February 2015).
34. Personalised Medicines: Hopes and Realities. Available online: https://royalsociety.org/policy/publications/2005/personalised-medicines/ (accessed on 1 March 2015).